Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition

Recursion Pharmaceuticals announced successful results for its lead drug candidate REC-994, showing it safe and tolerable for cerebral cavernous malformation patients in a Phase 2 study, though likely not satisfying investors closely watching the AI drug developer.